The Analytical Chemistry of Cannabis: Quality Assessment, Assurance, and Regulation of Medicinal Marijuana and Cannabinoid Preparations

The Analytical Chemistry of Cannabis: Quality Assessment, Assurance, and Regulation of Medicinal Marijuana and Cannabinoid Preparations

Volumn , Issue , 2015, Pages 1-115

  Thomas, Brian F ^a   ElSohly, Mahmoud A ^b,c  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMISTRY;

CHEMICAL CONTENT; DEGREE OF ORDER; FOSTER UNDERSTANDING; INDUSTRY STANDARDS; PERFORMANCE CHARACTERISTICS; QUALITY ASSESSMENT; TECHNICAL STAKEHOLDERS;

CHEMICAL ANALYSIS;

EID: 84959934791     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/C2014-0-03861-0     Document Type: Book

References (327)

1. Schultes R.E., Klein W.M., Plowman T., Lockwood T.E. Cannabis: An example of taxonomic neglect. Botanical Museum Leaflets, Harvard University 1974, 23(9):337-367.
2. Merlin M.D. Archaeological evidence for the tradition of psychoactive plant use in the old world. Econ Bot 2003, 57(3):295-323.
3. Jiang H.E., Li X., Zhao Y.X., et al. A new insight into Cannabis sativa (Cannabaceae) utilization from 2500-year-old Yanghai Tombs, Xinjiang, China. J Ethnopharmacol 2006, 108(3):414-422.
4. Doyle E., Spence A.A. Cannabis as a medicine?. Br J Anaesth 1995, 74(4):359-361.
5. Zuardi A.W. History of cannabis as a medicine: a review. Rev Bras Psiquiatr 2006, 28(2):153-157.
6. Mechoulam S., Lander N., Dikstein S., Carlini E.A., Blumenthal M. On the therapeutic possibilities of some cannabinoids. The Therapeutic Potential of Marihuana 1976, 36. Plenum Press, New York, NY. S. Cohen, R. Stillman (Eds.).
7. Duke J.A., Wain K.K. Medicinal Plants of the world, Computer index with more than 85.000 entries. Handbook of Medicinal Herbs 1981, 96. CRC Press, Boca Raton, FL. J.A. Duke (Ed.).
8. Abrams D.I., Jay C.A., Shade S.B., et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007, 68(7):515-521.
9. Pryce G., Baker D. Emerging properties of cannabinoid medicines in management of multiple sclerosis. Trends Neurosci 2005, 28(5):272-276.
10. Brenneisen R., Egli A., Elsohly M.A., Henn V., Spiess Y. The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 1996, 34(10):446-452.
11. Long L.E., Malone D.T., Taylor D.A. The pharmacological actions of cannabidiol. Drugs Future 2005, 30(7):747.
12. Sirikantaramas S., Taura F., Morimoto S., Shoyama Y. Recent advances in Cannabis sativa research: biosynthetic studies and its potential in biotechnology. Curr Pharm Biotechnol 2007, 8(4):237-243.
13. Mechoulam R., Carlini E.A. Toward drugs derived from cannabis. Naturwissenschaften 1978, 65(4):174-179.
14. Cunha J.M., Carlini E.A., Pereira A.E., et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980, 21(3):175-185.
15. Ranalli P., Di Candilo M., Mandolino G., Grassi G., Carboni A. Hemp for sustainable agricultural systems. Agro Food Ind Hi Tech 1999, 10(2):33-38.
16. Callaway J.C. Hempseed as a nutritional resource: an overview. Euphytica 2004, 140(1-2):65-72.
17. Kriese U., Schumann E., Weber W.E., Beyer M., Brühl L., Matthäus B. Oil content, tocopherol composition and fatty acid patterns of the seeds of 51 Cannabis sativa L. genotypes. Euphytica 2004, 137(3):339-351.
18. Small E., Marcus D. Hemp: a new crop with new uses for North America. Trends in New Crops and New Uses 2002, 284-326. ASHS Press, Alexandria, VA. J. Janick, A. Whipkey (Eds.).
19. Emboden W.A. Cannabis-a polytypic genus. Econ Bot 1974, 28(3):304-310.
20. Hillig K.W. A chemotaxonomic analysis of terpenoid variation in Cannabis. Biochem Syst Ecol 2004, 32(10):875-891.
21. Hillig K.W. Genetic evidence for speciation in Cannabis (Cannabaceae). Genet Resour Crop Evol 2005, 52(2):161-180.
22. Hillig K.W., Mahlberg P.G. A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae). Am J Bot 2004, 91(6):966-975.
23. Small E. Morphological variation of achenes of Cannabis. Can J Bot 1975, 53(10):978-987.
24. Small E. American law and the species problem in Cannabis: science and semantics. Bull Narc 1975, 27(3):1-20.
25. Small E., Cronquist A. A practical and natural taxonomy for Cannabis. Taxon 1976, 25(4):405.
26. Gilmore S., Peakall R., Robertson J. Short tandem repeat (STR) DNA markers are hypervariable and informative in Cannabis sativa: implications for forensic investigations. Forensic Sci Int 2003, 131(1):65-74.
27. Sakamoto K., Shimomura K., Komeda Y., Kamada H., Satoh S. A male-associated DNA sequence in a dioecious plant, Cannabis sativa L. Plant Cell Physiol 1995, 36(8):1549-1554.
28. Mandolino G., Carboni A., Forapani S., Faeti V., Ranalli P. Identification of DNA markers linked to the male sex in dioecious hemp (Cannabis sativa L.). Theor Appl Genet 1999, 98(1):86-92.
29. Flachowsky H., Schumann E., Weber W.E., Peil A. Application of AFLP for the detection of sex-specific markers in hemp. Plant Breed 2001, 120(4):305-309.
30. Törjék O., Bucherna N., Kiss E., et al. Novel male-specific molecular markers (MADC5, MADC6) in hemp. Euphytica 2002, 127(2):209-218.
31. Sakamoto K., Abe T., Matsuyama T., et al. RAPD markers encoding retrotransposable elements are linked to the male sex in Cannabis sativa L. Genome 2005, 48(5):931-936.
32. Techen N., Chandra S., Lata H., ElSohly M., Khan I. Genetic identification of female Cannabis sativa plants at early developmental stage. Planta Med 2010, 76(16):1938-1939.
33. Wood T.B., Spivey W.T.N., Easterfield T.H. Charas. The resin of Indian hemp. J Chem Soc, Trans 1896, 69:539-546.
34. Wood T.B., Spivey W.T.N., Easterfield T.H. Cannabinol. Part I. J Chem Soc 1899, 75:20-36.
35. Adams R., Baker B.R., Wearn R.B. Structure of cannabinol. III. Synthesis of cannabinol, 1-hydroxy-3-amyl-6,6,9-trimethyl-6-dibenzopyran. J Am Chem Soc 1940, 62:2204-2207.
36. Cahn R.S. Cannabis INDICA resin. III. Constitution of cannabinol. J Chem Soc 1932, 3:1342-1353.
37. Ghosh R., Todd A.R., Wilkinson S. Cannabis indica. Part V. The synthesis of cannabinol. J Chem Soc 1940, 1393-1396.
38. Adams R., Hunt M., Clark J.H. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. I. J Am Chem Soc 1940, 62(1):196-200.
39. Mechoulam R., Shvo Y. Hashish-I. Tetrahedron 1963, 19(12):2073-2078.
40. Gaoni Y., Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964, 86(8):1646-1647.
41. Turner C.E., Elsohly M.A., Boeren E.G. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod 1980, 43(2):169-234.
42. ElSohly M.A., Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005, 78(5):539-548.
43. Mandolino G., Bagatta M., Carboni A., Ranalli P., de Meijer E. Qualitative and quantitative aspects of the inheritance of chemical phenotype in Cannabis. J Ind Hemp 2003, 8(2):51-72.
44. Fetterman P.S., Keith E.S., Waller C.W., Guerrero O., Doorenbos N.J., Quimby M.W. Mississippi-grown Cannabis sativa L.: preliminary observation on chemical definition of phenotype and variations in tetrahydrocannabinol contentversus age, sex, and plant part. J Pharm Sci 1971, 60(8):1246-1249.
45. Small E., Beckstead H.D. Cannabinoid phenotypes in Cannabis sativa. Nature 1973, 245(5421):147-148.
46. Small E., Beckstead H.D. Common cannabinoid phenotypes in 350 stocks of Cannabis. Lloydia 1973, 36(2):144-165.
47. Fournier G., Richez-Dumanois C., Duvezin J., Mathieu J.P., Paris M. Identification of a new chemotype in Cannabis sativa: cannabigerol-dominant plants, biogenetic and agronomic prospects. Planta Med 1987, 53(3):277-280.
48. Hemphill J.K., Turner J.C., Mahlberg P.G. Cannabinoid content of individual plant organs from different geographical strains of Cannabis sativa L. J Nat Prod 1980, 43(1):112-122.
49. de Meijer E.P.M., van der Kamp H.J., van Eeuwijk F.A. Characterisation of Cannabis accessions with regard to cannabinoid content in relation to other plant characters. Euphytica 1992, 62(3):187-200.
50. Chandra S., Lata H., Khan I.A., Elsohly M.A. Photosynthetic response of Cannabis sativa L. to variations in photosynthetic photon flux densities, temperature and CO2 conditions. Physiol Mol Biol Plants 2008, 14(4):299-306.
51. Chandra S., Lata H., Khan I.A., ElSohly M.A. Variations in temperature response of photosynthesis in drug and fiber type varieties of Cannabis sativa L. Planta Med 2009, 75(04).
52. Mendoza M.A., Mills D.K., Lata H., Chandra S., ElSohly M.A., Almirall J.R. Genetic individualization of Cannabis sativa by a short tandem repeat multiplex system. Anal Bioanal Chem 2008, 393(2):719-726.
53. Bazzaz F.A., Dusek D., Seigler D.S., Haney A.W. Photosynthesis and cannabinoid content of temperate and tropical populations of Cannabis sativa. Biochem Syst Ecol 1975, 3:15-18.
54. Valle J.R., Vieira J.E., Aucelio J.G., Valio I.F. Influence of photoperiodism on cannabinoid content of Cannabis sativa L. Bull Narc 1978, 30(1):67-68.
55. Bócsa I., Máthé P., Hangyel L. Effect of nitrogen on tetrahydrocannabinol (THC) content in hemp (Cannabis sativa L.) leaves at different positions. J Int Hemp Assoc 1997, 4:80-81.
56. Pate D.W. Chemical ecology of Cannabis. J Int Hemp Assoc 1994, 1(29):32-37.
57. Shoyama Y., Hirano H., Oda M., Somehara T., Nishioka I. Cannabichromevarin and cannabigerovarin, two new propyl homologues of cannabichromene and cannabigerol. Chem Pharm Bull (Tokyo) 1975, 23(8):1894-1895.
58. Kajima M., Piraux M. The biogenesis of cannabinoids in Cannabis sativa. Phytochemistry 1982, 21(1):67-69.
59. Fellermeier M., Zenk M.H. Prenylation of olivetolate by a hemp transferase yields cannabigerolic acid, the precursor of tetrahydrocannabinol. FEBS Lett 1998, 427(2):283-285.
60. Flores-Sanchez I.J., Verpoorte R. Secondary metabolism in cannabis. Phytochem Rev 2008, 7(3):615-639.
61. Flores-Sanchez I.J., Verpoorte R. PKS activities and biosynthesis of cannabinoids and flavonoids in Cannabis sativa L. plants. Plant Cell Physiol 2008, 49(12):1767-1782.
62. Hartsel S.C., Loh W.H., Robertson L.W. Biotransformation of cannabidiol to cannabielsoin by suspension cultures of Cannabis sativa and Saccharum officinarum. Planta Med 1983, 48(1):17-19.
63. Mandolino G., Ranalli P. Advances in biotechnological approaches for hemp breeding and industry. Advances in Hemp Research 1999, 185-208. Haworth Press, New York, NY. P. Ranalli (Ed.).
64. Ślusarkiewicz-Jarzina A., Ponitka A., Kaczmarek Z. Influence of cultivar, explant source and plant growth regulator on callus induction and plant regeneration of Cannabis sativa L. Acta Biol Cracov Ser Bot 2005, 47(2):145-151.
65. Lata H., Chandra S., Khan I., ElSohly M.A. Thidiazuron-induced high-frequency direct shoot organogenesis of Cannabis sativa L. In Vitro Cell Dev Biol-Plant 2009, 45(1):12-19.
66. Lata H., Chandra S., Khan I.A., ElSohly M.A. Propagation through alginate encapsulation of axillary buds of Cannabis sativa L.-an important medicinal plant. Physiol Mol Biol Plants 2009, 15(1):79-86.
67. Lata H., Chandra S., Khan I.A., ElSohly M.A. Micropropagation of Cannabis sativa. Biotechnology of Cannabis sativa 2014, 82. Extreme publication Inc, New York, NY. 2nd ed. S.R. Zwenger (Ed.).
68. Wang R., He L.S., Xia B., Tong J.F., Li N., Peng F. A micropropagation system for cloning of hemp (Cannabis sativa L.) by shoot tip culture. Pak J Bot 2009, 41(2):603-608.
69. Lata H, Chandra S, Techen N, Khan IA, ElSohly MA. In vitro mass propagation of Cannabis sativa L.: a protocol refinement using a novel aromatic cytokinin meta-topolin and assessment of eco-physiological, biochemical and genetic fidelity of micropropagated plants (paper communicated). 2015.
70. Lata H., Bedir E., Hosick A., Ganzera M., Khan I., Moraes R.M. In vitro plant regeneration from leaf-derived callus of Cimicifuga racemosa. Planta Med 2002, 68(10):912-915.
71. Fisse J., Braut F., Cosson L., Paris M. Etude in vitro des capacities organogenetiques de tissues de Cannabis sativa L. Effet de differentes substances de crossance. Planta Med 1981, 15:217-223.
72. Lata H., Chandra S., Khan I.A., Elsohly M.A. High frequency plant regeneration from leaf derived callus of high Delta9-tetrahydrocannabinol yielding Cannabis sativa L. Planta Med 2010, 76(14):1629-1633.
73. Lata H., Chandra S., Techen N., Khan I.A., ElSohly M.A. Assessment of the genetic stability of micropropagated plants of Cannabis sativa by ISSR markers. Planta Med 2010, 76(1):97-100.
74. Lata H., Chandra S., Techen N., Wang Y.-H., Khan I.A. Molecular analysis of genetic fidelity in micropropagated plants of Stevia rebaudiana Bert. Using ISSR marker. AJPS 2013, 04(05):964-971.
75. Chandra S., Lata H., Mehmedic Z., Khan I.A., ElSohly M.A. Assessment of cannabinoids content in micropropagated plants of Cannabis sativa and their comparison with conventionally propagated plants and mother plant during developmental stages of growth. Planta Med 2010, 76(7):743-750.
76. Crop Genetic Resources: Conservation and Evaluation 1984, George Allen & Unwin (Publishers) Ltd, London. J.H.W. Holden, J.T. Williams (Eds.).
77. 9-tetrahydrocannabinol yielding elite clones of Cannabis sativa L. under slow growth conditions. Acta Physiol Plant 2012, 34(2):743-750.
78. 9-THC yielding varieties of Cannabis sativa L. J Appl Res Med Aromat Plants 2015, 2(2):39-47.
79. Chandra S., Lata H., Khan I.A., ElSohly M.A. Temperature response of photosynthesis in different drug and fiber varieties of Cannabis sativa L. Physiol Mol Biol Plants 2011, 17(3):297-303.
80. Kimball B.A. Carbon dioxide and agricultural yield: an assemblage and analysis of 430 prior observations. Agron J 1983, 75(5):779.
81. Kimball B.A. Carbon dioxide and agricultural yield: an assemblage and analysis of 770 prior observations. Water Conservation Lab Report 14, US Water Conservation Lab 1983, USDA-ARS, Phoenix, AZ.
82. 2 on crop yield. Carbon Dioxide Enrichment of Greenhouse Crops 1986, vol. 2:105-115. Physiology Yield and Economics, CRC Press, Inc, Boca Raton, FL.
83. 2 concentration. Vegetatio 1993, 104-105(1):77-97.
84. 2 enrichment in the face of environmental constraints: a review of the past 10 years' research. Agric For Meteorol 1994, 69(3-4):153-203.
85. 2. Physiol Mol Biol Plants 2011, 17(3):291-295.
86. Narayanaswami K., Golani H.C., Bami H.L., Dau R.D. Stability of Cannabis sativa L. samples and their extracts, on prolonged storage in Delhi. Bull Narc 1978, 30(4):57-69.
87. Harvey D.J. Stability of cannabinoids in dried samples of cannabis dating from around 1896-1905. J Ethnopharmacol 1990, 28(1):117-128.
88. Mehmedic Z., Chandra S., Slade D., et al. Potency trends of Delta9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci 2010, 55(5):1209-1217.
89. ElSohly M.A., Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005, 78(5):539-548.
90. Turner C.E., Elsohly M.A., Boeren E.G. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod 1980, 43(2):169-234.
91. McPartland J.M., Russo E.B. Cannabis and cannabis extracts: greater than the sum of their parts?. J Cannabis Ther 2001, 3/4:103-132.
92. Yamauchi T., Shoyama Y., Matsuo Y., Nishioka I. Cannabigerol monomethyl ether, a new component of hemp. Chem Pharm Bull (Tokyo) 1968, 16(6):1164-1165.
93. Shoyama Y., Hirano H., Makino H., Umekita N., Nishioka I. Cannabis. 10. Isolation and structures of 4 new propyl cannabinoid acids, tetrahydrocannabivarinic acid, cannabidivarinic acid, cannabichromevarinic acid, and cannabigerovarinic acid, from Thai Cannabis, MEAO variant. Chem Pharm Bull 1977, 25(9):2306-2311.
94. Shoyama Y., Yagi M., Nishioka I., Yamauchi T. Cannabis 8. Biosynthesis of cannabinoid acids. Phytochemistry 1975, 14(10):2189-2192.
95. ElSohly M.A., Gul W. Constituents of Cannabis sativa. Handbook of Cannabis 2014, 3-22. Oxford University Press, New York, NY. R.G. Pertwee (Ed.).
96. de Meijer E.P. The chemical phenotypes (chemotypes) of Cannabis. Handbook of Cannabis 2014, 89-110. Oxford University Press, New York, NY. R.G. Pertwee (Ed.).
97. Pacifico D., Miselli F., Carboni A., Moschella A., Mandolino G. Time course of cannabinoid accumulation and chemotype development during the growth of Cannabis sativa L. Euphytica 2008, 160(2):231-240.
98. de Meijer E.P.M., Hammond K.M. The inheritance of chemical phenotype in Cannabis sativa L. (II): Cannabigerol predominant plants. Euphytica 2005, 145(1-2):189-198.
99. de Meijer E.P.M., Hammond K.M., Micheler M. The inheritance of chemical phenotype in Cannabis sativa L. (III): variation in cannabichromene proportion. Euphytica 2009, 165(2):293-311.
100. de Meijer E.P.M., Hammond K.M., Sutton A. The inheritance of chemical phenotype in Cannabis sativa L. (IV): cannabinoid-free plants. Euphytica 2009, 168(1):95-112.
101. Russo E.B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011, 163(7):1344-1364.
102. Loza-Tavera H. Monoterpenes in essential oils. Biosynthesis and properties. Adv Exp Med Biol 1999, 464:49-62.
103. Dewick P.M. The biosynthesis of C5-C25 terpenoid compounds. Nat Prod Rep 2002, 19(2):181-222.
104. Rothschild M., Bergstrom G., Wangberg S.A. Cannabis sativa: volatile compounds from pollen and entire male and female plants of two variants, Northern Lights and Hawaian Indica. Bot J Linn Soc 2005, 147(4):387-397.
105. Ross S.A., ElSohly M.A. The volatile oil composition of fresh and air-dried buds of Cannabis sativa. J Nat Prod 1996, 59(1):49-51.
106. Docimo T., Consonni R., Coraggio I., Mattana M. Early phenylpropanoid biosynthetic steps in Cannabis sativa: link between genes and metabolites. Int J Mol Sci 2013, 14(7):13626-13644.
107. Flores-Sanchez I.J., Verpoorte R. PKS activities and biosynthesis of cannabinoids and flavonoids in Cannabis sativa L. plants. Plant Cell Physiol 2008, 49(12):1767-1782.
108. Vanhoenacker G., Van Rompaey P., De Keukeleire D., Sandra P. Chemotaxonomic features associated with flavonoids of cannabinoid-free cannabis (Cannabis sativa subsp. sativa L.) in relation to hops (Humulus lupulus L.). Nat Prod Lett 2002, 16(1):57-63.
109. Institute of Medicine. Washington DC: National Academy of Sciences; 1999.
110. Whiting P.F., Wolff R.F., Deshpande S., et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015, 313(24):2456-2473.
111. Gloss D., Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2014, 3. CD009270.
112. Hussain S.A., Zhou R., Jacobson C., et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav 2015, 47:138-141.
113. Esfandyari T., Camilleri M., Ferber I., Burton D., Baxter K., Zinsmeister A.R. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. Neurogastroenterol Motil 2006, 18(9):831-838.
114. Esfandyari T., Camilleri M., Busciglio I., Burton D., Baxter K., Zinsmeister A.R. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol 2007, 293(1):G137-145.
115. Storr M., Devlin S., Kaplan G.G., Panaccione R., Andrews C.N. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. Inflamm Bowel Dis 2014, 20(3):472-480.
116. Naftali T., Mechulam R., Lev L.B., Konikoff F.M. Cannabis for inflammatory bowel disease. Dig Dis 2014, 32(4):468-474.
117. Trezza V., Campolongo P. The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD). Front Behav Neurosci 2013, 7:100.
118. Betthauser K., Pilz J., Vollmer L.E. Use and effects of cannabinoids in military veterans with posttraumatic stress disorder. Am J Health Syst Pharm 2015, 72(15):1279-1284.
119. Razdan R.K. Structure-activity relationships in cannabinoids. Pharmacol Rev 1986, 38(2):75-149.
120. Ahmed S.A., Ross S.A., Slade D., et al. Cannabinoid ester constituents from high-potency Cannabis sativa. J Nat Prod 2008, 71(4):536-542.
121. Rock E.M., Kopstick R.L., Limebeer C.L., Parker L.A. Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus. Br J Pharmacol 2013, 170(3):641-648.
122. Rosenthaler S., Pohn B., Kolmanz C., et al. Differences in receptor binding affinity of several phytocannabinoids do not explain their effects on neural cell cultures. Neurotoxicol Teratol 2014, 46:49-56.
123. Verhoeckx K.C., Korthout H.A., van Meeteren-Kreikamp A.P., et al. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int Immunopharmacol 2006, 6(4):656-665.
124. Howlett A.C., Barth F., Bonner T.I., et al. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54(2):161-202.
125. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988, 34(5):605-613.
126. Howlett A.C. Cannabinoid inhibition of adenylate cyclase: relative activity of constituents and metabolites of marihuana. Neuropharmacology 1987, 26(5):507-512.
127. Slipetz D.M., O'Neill G.P., Favreau L., et al. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 1995, 48(2):352-361.
128. Sim L.J., Hampson R.E., Deadwyler S.A., Childers S.R. Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 1996, 16(24):8057-8066.
129. Breivogel C.S., Selley D.E., Childers S.R. Cannabinoid receptor agonist efficacy for stimulating [35S]GTPγS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem 1998, 273(27):16865-16873.
130. Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008, 153(2):199-215.
131. Adams I.B., Martin B.R. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996, 91(11):1585-1614.
132. Felder C.C., Veluz J.S., Williams H.L., Briley E.M., Matsuda L.A. Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 1992, 42(5):838-845.
133. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346(6284):561-564.
134. Gerard C.M., Mollereau C., Vassart G., Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991, 279(Pt 1):129-134.
135. Thomas A., Stevenson L.A., Wease K.N., et al. Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 2005, 146(7):917-926.
136. Hollister L.E. Structure-activity relationships in man of cannabis constituents, and homologs and metabolites of delta9-tetrahydrocannabinol. Pharmacology 1974, 11(1):3-11.
137. Gill E.W., Paton W.D., Pertwee R.G. Preliminary experiments on the chemistry and pharmacology of cannabis. Nature 1970, 228(5267):134-136.
138. Pertwee R.G., Thomas A., Stevenson L.A., et al. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol 2007, 150(5):586-594.
139. Thomas B.F., Gilliam A.F., Burch D.F., Roche M.J., Seltzman H.H. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 1998, 285(1):285-292.
140. Felder C.C., Joyce K.E., Briley E.M., et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995, 48(3):443-450.
141. Cascio M.G., Pertwee R.G. Known pharmacological actions of nine nonpsychotropic phytocannabinoids. Handbook of Cannabis 2014, 137-156. Oxford University Press, New York, NY. R.G. Pertwee (Ed.).
142. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996, 278(3):989-999.
143. Ryberg E., Larsson N., Sjogren S., et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007, 152(7):1092-1101.
144. Pertwee R.G. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 2010, 17(14):1360-1381.
145. Vaysse P.J., Gardner E.L., Zukin R.S. Modulation of rat brain opioid receptors by cannabinoids. J Pharmacol Exp Ther 1987, 241(2):534-539.
146. Kathmann M., Flau K., Redmer A., Trankle C., Schlicker E. Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn-Schmiedeberg's Arch Pharmacol 2006, 372(5):354-361.
147. Hejazi N., Zhou C., Oz M., Sun H., Ye J.H., Zhang L. Delta9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. Mol Pharmacol 2006, 69(3):991-997.
148. Ross H.R., Napier I., Connor M. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol. J Biol Chem 2008, 283(23):16124-16134.
149. De Petrocellis L., Ligresti A., Moriello A.S., et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011, 163(7):1479-1494.
150. Iannotti F.A., Hill C.L., Leo A., et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci 2014, 5(11):1131-1141.
151. Hill T.D., Cascio M.G., Romano B., et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism. Br J Pharmacol 2013, 170(3):679-692.
152. Zygmunt P.M., Andersson D.A., Hogestatt E.D. Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J Neurosci 2002, 22(11):4720-4727.
153. Engel M.A., Izydorczyk I., Mueller-Tribbensee S.M., Becker C., Neurath M.F., Reeh P.W. Inhibitory CB1 and activating/desensitizing TRPV1-mediated cannabinoid actions on CGRP release in rodent skin. Neuropeptides 2011, 45(3):229-237.
154. Thomas B.F., Compton D.R., Martin B.R. Characterization of the lipophilicity of natural and synthetic analogs of delta 9-tetrahydrocannabinol and its relationship to pharmacological potency. J Pharmacol Exp Ther 1990, 255(2):624-630.
155. Gertsch J., Leonti M., Raduner S., et al. Beta-caryophyllene is a dietary cannabinoid. Proc Natl Acad Sci U S A 2008, 105(26):9099-9104.
156. Tiwari M., Kakkar P. Plant derived antioxidants - Geraniol and camphene protect rat alveolar macrophages against t-BHP induced oxidative stress. Toxicol In Vitro 2009, 23(2):295-301.
157. Crowell P.L. Prevention and therapy of cancer by dietary monoterpenes. J Nutr 1999, 129(3):775S-778S.
158. Shoff S.M., Grummer M., Yatvin M.B., Elson C.E. Concentration-dependent increase of murine P388 and B16 population doubling time by the acyclic monoterpene geraniol. Cancer Res 1991, 51(1):37-42.
159. d'Alessio P.A., Ostan R., Bisson J.F., Schulzke J.D., Ursini M.V., Bene M.C. Oral administration of d-limonene controls inflammation in rat colitis and displays anti-inflammatory properties as diet supplementation in humans. Life Sci 2013, 92(24-26):1151-1156.
160. Barrett M.L., Gordon D., Evans F.J. Isolation from Cannabis sativa L. of cannflavin-a novel inhibitor of prostaglandin production. Biochem Pharmacol 1985, 34(11):2019-2024.
161. Vasanthi H.R., ShriShriMal N., Das D.K. Phytochemicals from plants to combat cardiovascular disease. Curr Med Chem 2012, 19(14):2242-2251.
162. Nieman D.C., Laupheimer M.W., Ranchordas M.K., Burke L.M., Stear S.J., Castell L.M. A-Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance-part 33. Br J Sports Med 2012, 46(8):618-620.
163. Cimino S., Sortino G., Favilla V., et al. Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid Med Cell Longev 2012, 2012. 632959.
164. Lübbert M., Kyereme J., Schöbel N., Beltrán L., Wetzel C.H., Hatt H. Transient receptor potential channels encode volatile chemicals sensed by rat trigeminal ganglion neurons. PLoS One 2013, 8(10):e77998.
165. Ohkawara S., Tanaka-Kagawa T., Furukawa Y., Nishimura T., Jinno H. Activation of the human transient receptor potential vanilloid subtype 1 by essential oils. Biol Pharm Bull 2010, 33(8):1434-1437.
166. Stotz S.C., Vriens J., Martyn D., Clardy J., Clapham D.E. Citral sensing by transient [corrected] receptor potential channels in dorsal root ganglion neurons. PLoS One 2008, 3(5):e2082.
167. Schlosburg J.E., O'Neal S.T., Conrad D.H., Lichtman A.H. CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action. Psychopharmacology (Berl) 2011, 216(3):323-331.
168. Schlosburg J.E., Boger D.L., Cravatt B.F., Lichtman A.H. Endocannabinoid modulation of scratching response in an acute allergenic model: a new prospective neural therapeutic target for pruritus. J Pharmacol Exp Ther 2009, 329(1):314-323.
169. Bedrocan. <> 2015 Accessed 28.09.15. http://www.bedrocan.nl/english/home.html.
170. Potter D.J. Cannabis horticulture. Handbook of Cannabis 2014, 65-88. Oxford University Press, New York, NY. R.G. Pertwee (Ed.).
171. Hazekamp A., Bastola K., Rashidi H., Bender J., Verpoorte R. Cannabis tea revisited: a systematic evaluation of the cannabinoid composition of cannabis tea. J Ethnopharmacol 2007, 113(1):85-90.
172. Klumpers L.E., Beumer T.L., van Hasselt J.G., et al. Novel Delta(9)-tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects. Br J Clin Pharmacol 2012, 74(1):42-53.
173. Zuardi A.W. History of cannabis as a medicine: a review. Rev Bras Psiquiatr 2006, 28:153-157.
174. Potter D.J. A review of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK. Drug Test Anal 2014, 6(1-2):31-38.
175. Grotenhermen F. Cannabinoids for therapeutic use. Am J Drug Deliv 2004, 2(4):229-240.
176. Duchi S., Ovadia H., Touitou E. Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis. J Neuroimmunol 2013, 258(1-2):32-40.
177. Al-Ghananeem A.M., Malkawi A.H., Crooks P.A. Bioavailability of Delta(9)-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits. Drug Dev Ind Pharm 2011, 37(3):329-334.
178. Paudel K.S., Hammell D.C., Agu R.U., Valiveti S., Stinchcomb A.L. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev Ind Pharm 2010, 36(9):1088-1097.
179. Valiveti S., Agu R.U., Hammell D.C., et al. Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. Eur J Pharm Biopharm 2007, 65(2):247-252.
180. Cichewicz D.L., Welch S.P., Smith F.L. Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol. Eur J Pharmacol 2005, 525(1-3):74-82.
181. Liput D.J., Hammell D.C., Stinchcomb A.L., Nixon K. Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder. Pharmacol Biochem Behav 2013, 111:120-127.
182. Valiveti S., Hammell D.C., Earles D.C., Stinchcomb A.L. In vitro/in vivo correlation studies for transdermal delta 8-THC development. J Pharm Sci 2004, 93(5):1154-1164.
183. Fischer K.M., Ward D.A., Hendrix D.V. Effects of a topically applied 2% delta-9-tetrahydrocannabinol ophthalmic solution on intraocular pressure and aqueous humor flow rate in clinically normal dogs. Am J Vet Res 2013, 74(2):275-280.
184. Merritt J.C., Perry D.D., Russell D.N., Jones B.F. Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma. J Clin Pharmacol 1981, 21(8-9 suppl):467S-471S.
185. Green K., Roth M. Ocular effects of topical administration of delta 9-tetrahydrocannabinol in man. Arch Ophthalmol (Chicago, Ill.: 1960) 1982, 100(2):265-267.
186. Naveh N., Weissman C., Muchtar S., Benita S., Mechoulam R. A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits. Graefes Arch Clin Exp Ophthalmol 2000, 238(4):334-338.
187. Merritt J.C., Olsen J.L., Armstrong J.R., McKinnon S.M. Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas. J Pharm Pharmacol 1981, 33(1):40-41.
188. Hippalgaonkar K., Gul W., ElSohly M.A., Repka M.A., Majumdar S. Enhanced solubility, stability, and transcorneal permeability of delta-8-tetrahydrocannabinol in the presence of cyclodextrins. AAPS PharmSciTech 2011, 12(2):723-731.
189. Green K.E., Kearse C.E. Ocular penetration of topical Delta9-tetrahydrocannabinol from rabbit corneal or cul-de-sac application site. Curr Eye Res 2000, 21(1):566-570.
190. Hingorani T., Gul W., Elsohly M., Repka M.A., Majumdar S. Effect of ion pairing on in vitro transcorneal permeability of a Delta(9)-tetrahydrocannabinol prodrug: potential in glaucoma therapy. J Pharm Sci 2012, 101(2):616-626.
191. Kearse E.C., Green K. Effect of vehicle upon in vitro transcorneal permeability and intracorneal content of Delta9-tetrahydrocannabinol. Curr Eye Res 2000, 20(6):496-501.
192. Colasanti B.K. A comparison of the ocular and central effects of delta 9-tetrahydrocannabinol and cannabigerol. J Ocul Pharmacol 1990, 6(4):259-269.
193. Hingorani T., Adelli G.R., Punyamurthula N., et al. Ocular disposition of the hemiglutarate ester prodrug of (9)-tetrahydrocannabinol from various ophthalmic formulations. Pharm Res 2013, 30(8):2146-2156.
194. Elsohly M.A., Little T.L., Hikal A., Harland E., Stanford D.F., Walker L. Rectal bioavailability of delta-9-tetrahydrocannabinol from various esters. Pharmacol Biochem Behav 1991, 40(3):497-502.
195. Brenneisen R., Egli A., Elsohly M.A., Henn V., Spiess Y. The effect of orally and rectally administered Δ 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther 1996, 34(10):446-452.
196. Mattes R.D., Shaw L.M., Edling-Owens J., Engelman K., Elsohly M.A. Bypassing the first-pass effect for the therapeutic use of cannabinoids. Pharmacol Biochem Behav 1993, 44(3):745-747.
197. Dussy F.E., Hamberg C., Luginbühl M., Schwerzmann T., Briellmann T.A. Isolation of Δ9-THCA-A from hemp and analytical aspects concerning the determination of Δ9-THC in cannabis products. Forensic Sci Int 2005, 149(1):3-10.
198. Ohlsson A., Lindgren J.E., Wahlen A., Agurell S., Hollister L.E., Gillespie H.K. Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980, 28(3):409-416.
199. Agurell S., Halldin M., Lindgren J.E., et al. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 1986, 38(1):21-43.
200. Huestis M.A. Human cannabinoid pharmacokinetics. Chem Biodivers 2007, 4(8):1770-1804.
201. Ohlsson A., Lindgren J.E., Wahlen A., Agurell S., Hollister L.E., Gillespie H.K. Single dose kinetics of deuterium labelled delta 1-tetrahydrocannabinol in heavy and light cannabis users. Biomed Mass Spectrom 1982, 9(1):6-10.
202. Wu T.-C., Tashkin D.P., Djahed B., Rose J.E. Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med 1988, 318(6):347-351.
203. Wang X., Derakhshandeh R., Narayan S., et al. Abstract 19538: brief exposure to Marijuana secondhand smoke impairs vascular endothelial function. Circulation 2014, 130(suppl 2):A19538.
204. Perez-Reyes M., Lipton M.A., Timmons M.C., Wall M.E., Brine D.R., Davis K.H. Pharmacology of orally administered Δ9-tetrahydrocannabinol. Clin Pharmacol Ther 1973, 14(1):48-55.
205. Caterina M.J. TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation. ACS Chem Neurosci 2014, 5(11):1107-1116.
206. Lynn A.B., Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 1994, 268(3):1612-1623.
207. Olah A., Toth B.I., Borbiro I., et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest 2014, 124(9):3713-3724.
208. Biro T., Toth B.I., Hasko G., Paus R., Pacher P. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci 2009, 30(8):411-420.
209. De La Ossa D.H.P., Gil-Alegre M.E., Ligresti A., et al. Preparation and characterization of Δ9-tetrahydrocannabinol-loaded biodegradable polymeric microparticles and their antitumoral efficacy on cancer cell lines. J Drug Target 2013, 21(8):710-718.
210. Hernán Pérez de la Ossa D., Lorente M., Gil-Alegre M.E., et al. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. PLoS One 2013, 8(1).
211. Martín-Banderas L., Muñoz-Rubio I., Prados J., et al. In vitro and in vivo evaluation of Δ9-tetrahidrocannabinol/PLGA nanoparticles for cancer chemotherapy. Int J Pharm 2015, 487(1-2):205-212.
212. Hazekamp A., Fischedick J.T. Cannabis-from cultivar to chemovar. Drug Test Anal 2012, 4(7-8):660-667.
213. Potter D.J. Cannabis horticulture. Handbook of Cannabis 2014, 65-88. Oxford University Press, New York, NY. R.G. Pertwee (Ed.).
214. Potter D.J. A review of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK. Drug Test Anal 2014, 6(1-2):31-38.
215. Stott C.G., Guy G.W. Cannabinoids for the pharmaceutical industry. Euphytica 2004, 140(1-2):83-93.
216. Hazekamp A., Pappas G. Self-medication with Cannabis. Handbook of Cannabis 2014, 319-338. Oxford University Press, New York, NY. R.G. Pertwee (Ed.).
217. Broséus J., Anglada F., Esseiva P. The differentiation of fibre- and drug type Cannabis seedlings by gas chromatography/mass spectrometry and chemometric tools. Forensic Sci Int 2010, 200(1-3):87-92.
218. Fischedick J.T., Hazekamp A., Erkelens T., Choi Y.H., Verpoorte R. Metabolic fingerprinting of Cannabis sativa L., cannabinoids and terpenoids for chemotaxonomic and drug standardization purposes. Phytochemistry 2010, 71(17-18):2058-2073.
219. Ilias Y., Rudaz S., Mathieu P., Christen P., Veuthey J.L. Extraction and analysis of different Cannabis samples by headspace solid-phase microextraction combined with gas chromatography-mass spectrometry. J Sep Sci 2005, 28(17):2293-2300.
220. Omar J., Olivares M., Amigo J.M., Etxebarria N. Resolution of co-eluting compounds of Cannabis sativa in comprehensive two-dimensional gas chromatography/mass spectrometry detection with multivariate curve resolution-alternating least squares. Talanta 2014, 121:273-280.
221. 1H NMR and HPLC/DAD for Cannabis sativa L. chemotype distinction, extract profiling and specification. Talanta 2015, 140:150-165.
222. Rothschild M., Bergstrom G., Wangberg S.A. Cannabis sativa: volatile compounds from pollen and entire male and female plants of two variants, Northern Lights and Hawaian Indica. Bot J Linn Soc 2005, 147(4):387-397.
223. van der Kooy F., Maltese F., Choi Y.H., Kim H.K., Verpoorte R. Quality control of herbal material and phytopharmaceuticals with MS and NMR based metabolic fingerprinting. Planta Med 2009, 75(7):763-775.
224. 2 extraction and on-line fractionation. Ind Crop Prod 2014, 58:99-103.
225. Happyana N., Agnolet S., Muntendam R., Van Dam A., Schneider B., Kayser O. Analysis of cannabinoids in laser-microdissected trichomes of medicinal Cannabis sativa using LCMS and cryogenic NMR. Phytochemistry 2013, 87:51-59.
226. Hillig K.W. A chemotaxonomic analysis of terpenoid variation in Cannabis. Biochem Syst Ecol 2004, 32(10):875-891.
227. Pacifico D., Miselli F., Carboni A., Moschella A., Mandolino G. Time course of cannabinoid accumulation and chemotype development during the growth of Cannabis sativa L. Euphytica 2008, 160(2):231-240.
228. Taschwer M, Schmid MG. Determination of the relative percentage distribution of THCA and Δ9-THC in herbal cannabis seized in Austria-impact of different storage temperatures on stability. Forensic Sci Int. 2015;254:167-171.
229. Verhoeckx K.C., Korthout H.A., van Meeteren-Kreikamp A.P., et al. Unheated Cannabis sativa extracts and its major compound THC-acid have potential immuno-modulating properties not mediated by CB1 and CB2 receptor coupled pathways. Int Immunopharmacol 2006, 6(4):656-665.
230. Organization WH Quality Control Methods for Medicinal Plant Materials 1998, 214. World Health Organization, England.
231. Administration USFaD Guidance for Industry: Botanical Drug Development (Draft Guidance) 2015, Office of Communications, Division of Drug Information, Silver Spring, MD. Research CfDEa (Ed.).
232. USP-NFU-N. Rockville, MD: United States Pharmacopeia Convention; 2015.
233. Wianowska D., Dawidowicz A.L., Kowalczyk M. Transformations of tetrahydrocannabinol, tetrahydrocannabinolic acid and cannabinol during their extraction from Cannabis sativa L. J Anal Chem 2015, 70(8):920-925.
234. Díaz-Maroto M.C., Pérez-Coello M.S., Cabezudo M.D. Supercritical carbon dioxide extraction of volatiles from spices: comparison with simultaneous distillation-extraction. J Chromatogr A 2002, 947(1):23-29.
235. Omar J., Olivares M., Alzaga M., Etxebarria N. Optimisation and characterisation of marihuana extracts obtained by supercritical fluid extraction and focused ultrasound extraction and retention time locking GC-MS. J Sep Sci 2013, 36(8):1397-1404.
236. 2 extraction of oil. J Food Sci Technol 2015, 52(3):1748-1753.
237. Kauppila T.J., Flink A., Laakkonen U.M., Aalberg L., Ketola R.A. Direct analysis of cannabis samples by desorption atmospheric pressure photoionization-mass spectrometry. Drug Test Anal 2013, 5(3):186-190.
238. Politi M., Peschel W., Wilson N., Zloh M., Prieto J.M., Heinrich M. Direct NMR analysis of cannabis water extracts and tinctures and semi-quantitative data on delta9-THC and delta9-THC-acid. Phytochemistry 2008, 69(2):562-570.
239. Brenneisen R., ElSohly M.A. Chromatographic and spectroscopic profiles of Cannabis of different origins: part I. J Forensic Sci 1988, 33(6):1385-1404.
240. Chandra S., Lata H., Mehmedic Z., Khan I.A., Elsohly M.A. Assessment of cannabinoids content in micropropagated plants of Cannabis sativa and their comparison with conventionally propagated plants and mother plant during developmental stages of growth. Planta Med 2010, 76(7):743-750.
241. Gambaro V., Dell'Acqua L., Farè F., Froldi R., Saligari E., Tassoni G. Determination of primary active constituents in Cannabis preparations by high-resolution gas chromatography/flame ionization detection and high-performance liquid chromatography/UV detection. Anal Chim Acta 2002, 468(2):245-254.
242. Gröger T., Schäffer M., Pütz M., et al. Application of two-dimensional gas chromatography combined with pixel-based chemometric processing for the chemical profiling of illicit drug samples. J Chromatogr A 2008, 1200(1):8-16.
243. Ross S.A., Elsohly H.N., Elkashoury E.A., Elsohly M.A. Fatty acids of cannabis seeds. Phytochem Anal 1996, 7(6):279-283.
244. Tipparat P., Natakankitkul S., Chamnivikaipong P., Chutiwat S. Characteristics of cannabinoids composition of Cannabis plants grown in Northern Thailand and its forensic application. Forensic Sci Int 2012, 215(1-3):164-170.
245. Fischedick J.T., Glas R., Hazekamp A., Verpoorte R. A qualitative and quantitative HPTLC densitometry method for the analysis of cannabinoids in Cannabis sativa L. Phytochem Anal: PCA 2009, 20(5):421-426.
246. Wohlfarth A., Mahler H., Auwarter V. Rapid isolation procedure for Delta9-tetrahydrocannabinolic acid A (THCA) from Cannabis sativa using two flash chromatography systems. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879(28):3059-3064.
247. Zhou Q., Gao B., Zhang X., Xu Y., Shi H., Yu L. Chemical profiling of triacylglycerols and diacylglycerols in cow milk fat by ultra-performance convergence chromatography combined with a quadrupole time-of-flight mass spectrometry. Food Chem 2014, 143:199-204.
248. Hudalla CJ. Analytical Testing for the cannabis industry: application of ultraperformance convergence chromatography (UPC2). In: CoSMoS: Conference on Small Molecule Science; Williamsburg, VA; 2014.
249. Van der Kooy F., Pomahacova B., Verpoorte R. Cannabis smoke condensate I: the effect of different preparation methods on tetrahydrocannabinol levels. Inhal Toxicol 2008, 20(9):801-804.
250. Fairlie K., Fox B.L. Rapid, quantitative determination of tetrahydrocannabinol in marihuana by gas chromatography. J Chromatogr Sci 1976, 14(7):334-335.
251. Hewavitharana A.K., Golding G., Tempany G., King G., Holling N. Quantitative GC-MS analysis of D(9)-tetrahydrocannabinol in fiber hemp varieties. J Anal Toxicol 2005, 29(4):258-261.
252. Barni Comparini I., Centini F. Packed column chromatography, high-resolution gas-chromatography and high pressure liquid chromatography in comparison for the analysis of cannabis constituents. Forensic Sci Int 1983, 21(2):129-137.
253. Song C.H., Kanter S.L., Hollister L.E. Extraction and gas chromatographic quantification of tetrahydrocannabinol from marihuana. Res Commun Chem Pathol Pharmacol 1970, 1(3):375-382.
254. Aizpurua-Olaizola O., Omar J., Navarro P., Olivares M., Etxebarria N., Usobiaga A. Identification and quantification of cannabinoids in Cannabis sativa L. plants by high performance liquid chromatography-mass spectrometry. Anal Bioanal Chem 2014, 406(29):7549-7560.
255. De Backer B., Debrus B., Lebrun P., et al. Innovative development and validation of an HPLC/DAD method for the qualitative and quantitative determination of major cannabinoids in cannabis plant material. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877(32):4115-4124.
256. Smith R.N., Vaughan C.G. High-pressure liquid chromatography of cannabis. Quantitative analysis of acidic and neutral cannabinoids. J Chromatogr 1976, 129:347-354.
257. Hazekamp A., Choi Y.H., Verpoorte R. Quantitative analysis of cannabinoids from Cannabis sativa using 1H-NMR. Chem Pharm Bull (Tokyo) 2004, 52(6):718-721.
258. Upton R, Dayu RH, Craker L, et al., eds. Cannabis inflorescence (Cannabis spp.): Standards of Identify, Analysis, and Quality Control. Scott's Valley, CA: American Herbal Pharmacopeia, ed; 2013.
259. Schneider S., Bebing R., Dauberschmidt C. Detection of pesticides in seized illegal cannabis plants. Anal Methods 2014, 6(2):515-520.
260. Sullivan N., Elzinga S., Raber J.C. Determination of pesticide residues in cannabis smoke. J Toxicol 2013, 2013:378168.
261. Lorenz W., Bahadir M., Korte F. Thermolysis of pesticide residues during tobacco smoking. Chemosphere 1987, 16(2-3):521-522.
262. Stone D. Cannabis, pesticides and conflicting laws: the dilemma for legalized States and implications for public health. Regul Toxicol Pharmacol: RTP 2014, 69(3):284-288.
263. United States Environmental Protection Agency. Residue Analytical Methods. <> Accessed 14.10.15. http://www2.epa.gov/pesticide-analytical-methods/analytical-methods-measuring-pesticide-residues.
264. Administration USFaD. Bacteriological Analytical Manual. <> Accessed 14.10.15. http://www.fda.gov/Food/FoodScienceResearch/LaboratoryMethods/ucm2006949.htm.
265. Angelova V., Ivanova R., Delibaltova V., Ivanov K. Bio-accumulation and distribution of heavy metals in fibre crops (flax, cotton and hemp). Ind Crop Prod 2004, 19(3):197-205.
266. Khan M.A., Wajid A., Noor S., Khattak F.K., Akhter S., Rahman I.U. Effect of soil contamination on some heavy metals content of Cannabis sativa. J Chem Soc Pak 2008, 30(6):805-809.
267. Shi G., Liu C., Cui M., Ma Y., Cai Q. Cadmium tolerance and bioaccumulation of 18 hemp accessions. Appl Biochem Biotechnol 2012, 168(1):163-173.
268. Zavada J, Bouchal T, Fryc J, Nadkanska H, Blazek V. Cannabis sativa as a biosorbent for the removal of heavy metals from aqueous solutions. In: Paper presented at: International Multidisciplinary Scientific GeoConference Surveying Geology and Mining Ecology Management, SGEM2013.
269. Zerihun A., Chandravanshi B.S., Debebe A., Mehari B. Levels of selected metals in leaves of Cannabis sativa L. cultivated in Ethiopia. SpringerPlus 2015, 4(1).
270. Zuardi A.W. History of cannabis as a medicine: a review. Rev Bras Psiquiatr 2006, 28:153-157.
271. Trofin I.G., Dabija G., Vaireanu D.I., Filipescu L. Long-term storage and cannabis oil stability. Rev Chim 2012, 63(3):293-297.
272. Gaoni Y., Mechoulam R. Hashish-VII. Tetrahedron 1966, 22(4):1481-1488.
273. Adams R., Pease D.C., Cain C.K., et al. Conversion of cannabidiol to a product with marihuana activity. A type reaction for synthesis of analogous substances. J Am Chem Soc 1940, 62(8):2245-2246.
274. Watanabe K., Itokawa Y., Yamaori S., et al. Conversion of cannabidiol to Δ9-tetrahydrocannabinol and related cannabinoids in artificial gastric juice, and their pharmacological effects in mice. Forensic Toxicol 2007, 25(1):16-21.
275. Martin-Santos R., Crippa J.A., Batalla A., et al. Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Curr Pharm Des 2012, 18(32):4966-4979.
276. Manini A.F., Yiannoulos G., Bergamaschi M.M., et al. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous Fentanyl in humans. J Addict Med 2015, 9(3):204-210.
277. Vandrey R., Raber J.C., Raber M.E., Douglass B., Miller C., Bonn-Miller M.O. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA 2015, 313(24):2491-2493.
278. United States Food and Drug Administration. Warning letters and test results. <> 2015. http://www.fda.gov/NewsEvents/PublicHealthFocus/ucm435591.htm.
279. MacCoun R.J., Mello M.M. Half-baked-the retail promotion of marijuana edibles. N Engl J Med 2015, 372(11):989-991.
280. Berger E. Legal marijuana and pediatric exposure pot edibles implicated in spike in child emergency department visits. Ann Emerg Med 2014, 64(4):A19-A21.
281. Potera C. Kids and marijuana edibles: a worrisome trend emerges. Am J Nurs 2015, 115(9):15.
282. Organization WH. WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants, <> 2003 Accessed 16.11.15. http://apps.who.int/iris/bitstream/10665/42783/1/9241546271.pdf.
283. Agency EM. Guideline on good agricultural and collection practice for starting materials of herbal origin. <> 2006 Accessed 16.11.15. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003362.pdf.
284. Potter D.J. Cannabis horticulture. Handbook of Cannabis 2014, 65-88. Oxford University Press, New York, NY. R.G. Pertwee (Ed.).
285. Stott C.G., Guy G.W. Cannabinoids for the pharmaceutical industry. Euphytica 2004, 140(1-2):83-93.
286. Potter D.J. A review of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK. Drug Test Anal 2014, 6(1-2):31-38.
287. Clarke R.C. Marijuana Botany: An Advanced Study: The Propagation and Breeding of Distinctive Cannabis 1981, Ronin Publishing, Berkeley, CA.
288. Upton R., Craker L., ElSohly M., Romm A., Russo E., Sexton M. Cannabis Infloresence 2013, American Herbal Pharmacopoeia, Scotts Valley, CA.
289. Taschwer M, Schmid MG. Determination of the relative percentage distribution of THCA and Δ9-THC in herbal cannabis seized in Austria-Impact of different storage temperatures on stability. Forensic Sci Int. 2015;254:167-171.
290. Organization WH. WHO guidelines on good manufacturing practices (GMP) for herbal medicines. <> 2007 Accessed 16.11.15. http://apps.who.int/medicinedocs/documents/s14215e/s14215e.pdf.
291. Administration USFaD Guidance for Industry: Botanical Drug Development (Draft Guidance) 2015, Office of Communications, Division of Drug Information, Silver Spring, MD. Research CfDEa (Ed.).
292. Gieringer D., St Laurent J., Goodrich S. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J Cannabis Ther 2004, 4(1):7-27.
293. Pomahacova B., Van Der Kooy F., Verpoorte R. Cannabis smoke condensate III: the cannabinoid content of vaporised Cannabis sativa cannabinoid content of vaporised Cannabis sativa. Inhal Toxicol 2009, 21(13):1108-1112.
294. Hartman R.L., Brown T.L., Milavetz G., et al. Controlled cannabis vaporizer administration: blood and plasma cannabinoids with and without alcohol. Clin Chem 2015, 61(6):850-869.
295. Budney A.J., Sargent J.D., Lee D.C. Vaping cannabis (marijuana): parallel concerns to e-cigs?. Addiction 2015, 110:1699-1704.
296. Giroud C., de Cesare M., Berthet A., Varlet V., Concha-Lozano N., Favrat B. E-Cigarettes: a review of new trends in cannabis use. Int J Environ Res Public Health 2015, 12(8):9988-10008.
297. Agu R.U., Ugwoke M.I. In vitro and in vivo testing methods for respiratory drug delivery. Expert Opin Drug Deliv 2011, 8(1):57-69.
298. Darquenne C. Aerosol deposition in health and disease. J Aerosol Med Pulm Drug Deliv 2012, 25(3):140-147.
299. Pilcer G., Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 2010, 392(1-2):1-19.
300. Bonuccelli C.M. Stable solutions for marijuana analysis. J Pharm Sci 1979, 68(2):262-263.
301. Smith R.N., Vaughan C.G. The decomposition of acidic and neutral cannabinoids in organic solvents. J Pharm Pharmacol 1977, 29(5):286-290.
302. Turner C.E., Henry J.T. Constituents of Cannabis sativa L. IX: stability of synthetic and naturally occurring cannabinoids in chloroform. J Pharm Sci 1975, 64(2):357-359.
303. Flora K.P., Cradock J.C., Davignon J.P. Determination of delta 9-tetrahydrocannabinol in pharmaceutical vehicles by high-performance liquid chromatography. J Chromatogr 1981, 206(1):117-123.
304. Fairbairn J.W., Liebmann J.A., Rowan M.G. The stability of cannabis and its preparations on storage. J Pharm Pharmacol 1976, 28(1):1-7.
305. Lewis G.S., Turner C.E. Constituents of Cannabis sativa L. XIII: stability of dosage form prepared by impregnating synthetic (-)-delta 9-trans-tetrahydrocannabinol on placebo cannabis plant material. J Pharm Sci 1978, 67(6):876-878.
306. Narayanaswami K., Golani H.C., Bami H.L., Dau R.D. Stability of Cannabis sativa L. samples and their extracts, on prolonged storage in Delhi. Bull Narc 1978, 30(4):57-69.
307. Taschwer M., Schmid M.G. Determination of the relative percentage distribution of THCA and Delta(9)-THC in herbal cannabis seized in Austria-impact of different storage temperatures on stability. Forensic Sci Int 2015, 254:167-171.
308. Lindholst C. Long term stability of cannabis resin and cannabis extracts. Aust J Forensic Sci 2010, 42(3):181-190.
309. Booth M. Cannabis: A History 2003, St. Martin's Press, New York, NY.
310. Mead A.P. International control of cannabis. Handbook of Cannabis 2014, 44-64. Oxford University Press, New York, NY. R.G. Pertwee (Ed.).
311. Stott C.G., Guy G.W. Cannabinoids for the pharmaceutical industry. Euphytica 2004, 140(1-2):83-93.
312. Reardon S. Marijuana gears up for production high in US labs. Nature 2015, 519(7543):269-270.
313. Bewley-Taylor D.R. Towards revision of the UN drug control conventions: harnessing like-mindedness. Int J Drug Policy 2013, 24(1):60-68.
314. Stone D. Cannabis, pesticides and conflicting laws: the dilemma for legalized States and implications for public health. Regul Toxicol Pharmacol: RTP 2014, 69(3):284-288.
315. Hill K.P. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA 2015, 313(24):2474-2483.
316. Sastre-Garriga J., Vila C., Clissold S., Montalban X. THC and CBD oromucosal spray (Sativex(R)) in the management of spasticity associated with multiple sclerosis. Expert Rev Neurother 2011, 11(5):627-637.
317. Hussain S.A., Zhou R., Jacobson C., et al. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav 2015, 47:138-141.
318. Wilkinson S.T., Stefanovics E., Rosenheck R.A. Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder. J Clin Psychiatry 2015, 76(9):1174-1180.
319. Adams R., Loewe S., Pease D.C., et al. Structure of cannabidiol. VIII. Position of the double bonds in cannabidiol. Marihuana activity of tetrahydro-cannabinols [1]. J Am Chem Soc 1940, 62(9):2566-2567.
320. Gaoni Y., Mechoulam R. Hashish-VII. Tetrahedron 1966, 22(4):1481-1488.
321. Devane W.A., Dysarz Iii F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988, 34(5):605-613.
322. Devane W.A., Hanus L., Breuer A., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258(5090):1946-1949.
323. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346(6284):561-564.
324. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365(6441):61-65.
325. Borgelt L.M., Franson K.L., Nussbaum A.M., Wang G.S. The pharmacologic and clinical effects of medical cannabis. Pharmacother: J Hum Pharmacol Drug Ther 2013, 33(2):195-209.
326. Danovitch I., Gorelick D.A. State of the art treatments for cannabis dependence. Psychiatr Clin North Am 2012, 35(2):309-326.
327. Hall W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use?. Addiction 2015, 110(1):19-35.